Brexanolone
FDA-approved product (solution, intravenous), marketed as Zulresso.
- Registered studies
- 26
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Depressive disorder
- Major depressive disorder
- Postpartum depression
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antidepressants
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli10.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
26registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Brexanolone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
NCT02942004 · start 2016-08-01
Registered record
- Registry ID
- NCT02942004
- Conditions
- Postpartum Depression
- Interventions
- Placebo; SAGE-547 60 μg/kg/h; SAGE-547 90 μg/kg/h
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-08-01
- Completion
- 2017-10-19
- Enrolment
- 138
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostpartum DepressionInterventionPlacebo; SAGE-547 60 μg/kg/h; SAGE-547 90 μg/kg/hPhasePhase 3Registry statusCompletedA Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
NCT02942017 · start 2016-07
Registered record
- Registry ID
- NCT02942017
- Conditions
- Postpartum Depression
- Interventions
- Placebo; SAGE-547 90 μg/kg/h
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-07
- Completion
- 2017-10-11
- Enrolment
- 108
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostpartum DepressionInterventionPlacebo; SAGE-547 90 μg/kg/hPhasePhase 3Registry statusCompletedA Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
NCT02614547 · start 2015-12-15
Registered record
- Registry ID
- NCT02614547
- Conditions
- Severe Postpartum Depression
- Interventions
- SAGE-547; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-12-15
- Completion
- 2016-06-22
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSevere Postpartum DepressionInterventionSAGE-547; PlaceboPhasePhase 2Registry statusCompletedTreatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone
NCT02603926 · start 2015-10
Registered record
- Registry ID
- NCT02603926
- Conditions
- Fragile X-associated Tremor/Ataxia Syndrome
- Interventions
- Allopregnanolone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-10
- Completion
- 2017-12
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFragile X-associated Tremor/Ataxia SyndromeInterventionAllopregnanolonePhasePhase 2Registry statusCompletedA Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT02477618 · start 2015-06
Registered record
- Registry ID
- NCT02477618
- Conditions
- Super-Refractory Status Epilepticus
- Interventions
- SAGE-547; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-06
- Completion
- 2017-08-11
- Enrolment
- 132
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSuper-Refractory Status EpilepticusInterventionSAGE-547; PlaceboPhasePhase 3Registry statusCompletedEvaluate SAGE-547 in Female Participants With Severe Postpartum Depression
NCT02285504 · start 2015-01-07
Registered record
- Registry ID
- NCT02285504
- Conditions
- Postpartum Depression
- Interventions
- SAGE-547
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-01-07
- Completion
- 2015-06-05
- Enrolment
- 4
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostpartum DepressionInterventionSAGE-547PhasePhase 2Registry statusCompletedEvaluate SAGE-547 in Participants With Essential Tremor
NCT02277106 · start 2014-09-23
Registered record
- Registry ID
- NCT02277106
- Conditions
- Essential Tremor
- Interventions
- SAGE-547; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-09-23
- Completion
- 2015-08-14
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential TremorInterventionSAGE-547; PlaceboPhasePhase 2Registry statusCompletedStudy to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
NCT02052739 · start 2014-03-21
Registered record
- Registry ID
- NCT02052739
- Conditions
- Super-refractory Status Epilepticus
- Interventions
- SAGE-547
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2014-03-21
- Completion
- 2015-05-03
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSuper-refractory Status EpilepticusInterventionSAGE-547PhasePhase 1 / Phase 2Registry statusCompletedNational Pregnancy Registry for Psychiatric Medications
NCT01246765 · start 2008-11
Registered record
- Registry ID
- NCT01246765
- Conditions
- Pregnant Women; Psychotropic Drugs
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2008-11
- Completion
- 2033-12
- Enrolment
- 5,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPregnant Women; Psychotropic DrugsInterventionNot recordedPhaseNot recordedRegistry statusRecruitingAn Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
NCT02433314
Registered record
- Registry ID
- NCT02433314
- Conditions
- Super-Refractory Status Epilepticus
- Interventions
- SAGE-547
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSuper-Refractory Status EpilepticusInterventionSAGE-547PhaseNot recordedRegistry statusNo longer availableExpanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
NCT03924492
Registered record
- Registry ID
- NCT03924492
- Conditions
- Postpartum Depression
- Interventions
- ZULRESSO (brexanolone) injection
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- Approved for marketing
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostpartum DepressionInterventionZULRESSO (brexanolone) injectionPhaseNot recordedRegistry statusApproved for marketing